Actualités Medexus Pharmaceuticals Inc - MDP | Actions TSX Venture Exchange

Medexus to Participate in the 33rd Annual ROTH Conference on March 15-17, 2021

TORONTO, CHICAGO and MONTREAL, March 08, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company”...

Medexus Achieves Record Revenue of $31.5 Million for the Third Quarter Fiscal 2021

TORONTO, CHICAGO and MONTREAL, March 01, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company”...

Medexus Announces Expanded Availability of Gleolan® in Canada

TORONTO and CHICAGO and MONTREAL, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the...

Medexus Schedules Third Quarter Fiscal 2021 Conference Call

TORONTO and CHICAGO and MONTREAL, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the...

Medexus Announces Closing of $32.5 Million Public Offering, Including Exercise in Full of Over-Allotment Option

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO...

Medexus to Present at the Winter Wonderland Conference- Best Ideas from the Buy-Side

TORONTO, CHICAGO and MONTREAL, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company”...

Medexus Announces Upsize to Previously Announced Bought Deal Public Offering

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO...

Medexus Announces $20 Million Bought Deal Public Offering of Units

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO...

Medexus Pharmaceuticals and medac GmbH enter into a License Agreement for First-in-Class Conditioning Agent for Hematopoietic...

Orphan Designated Drug with August 2021 PDUFA date Management to host conference call at 10:00 AM Eastern Time...

Medexus Announces Renewal and Expansion of Canadian Distribution Agreement for NYDA®

TORONTO, CHICAGO and MONTREAL, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company”...

Medexus Submits Application to List on the Nasdaq

TORONTO, CHICAGO and MONTREAL, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company”...

Medexus Engages Independent Trading Group for Market Making Services

TORONTO and CHICAGO and MONTREAL, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the...

Medexus Announces Annual Equity Incentive Grants to Non-Executive Directors

TORONTO and CHICAGO and MONTREAL, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the...

Medexus Enters into Exclusive License to Register and Commercialize Triamcinolone Hexacetonide (TH) in the United States with...

TORONTO and CHICAGO and MONTREAL, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the...

Medexus to Present at The 13th Annual LD Micro Main Event Conference on December 15th

TORONTO and CHICAGO and MONTREAL, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the...

	Prix en temps réel	Carnet d'ordres
BATS Europe
Chi-X Europe
Euronext

	Prix en temps réel	Carnet d'ordres
BATS Europe
Chi-X Europe
Euronext

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Medexus Pharmaceuticals Inc (MDP)

Votre Hub pour des idées et discussions en direct en temps réel

MDP Actualités

Medexus to Participate in the 33rd Annual ROTH Conference on March 15-17, 2021

Medexus Achieves Record Revenue of $31.5 Million for the Third Quarter Fiscal 2021

Medexus Announces Expanded Availability of Gleolan® in Canada

Medexus Schedules Third Quarter Fiscal 2021 Conference Call

Medexus Announces Closing of $32.5 Million Public Offering, Including Exercise in Full of Over-Allotment Option

Medexus to Present at the Winter Wonderland Conference- Best Ideas from the Buy-Side

Medexus Announces Upsize to Previously Announced Bought Deal Public Offering

Medexus Announces $20 Million Bought Deal Public Offering of Units

Medexus Pharmaceuticals and medac GmbH enter into a License Agreement for First-in-Class Conditioning Agent for Hematopoietic...

Medexus Announces Renewal and Expansion of Canadian Distribution Agreement for NYDA®

Medexus Submits Application to List on the Nasdaq

Medexus Engages Independent Trading Group for Market Making Services

Medexus Announces Annual Equity Incentive Grants to Non-Executive Directors

Medexus Enters into Exclusive License to Register and Commercialize Triamcinolone Hexacetonide (TH) in the United States with...

Medexus to Present at The 13th Annual LD Micro Main Event Conference on December 15th

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

BLACK FRIDAY

Jusqu'à 65% de réduction sur Intégral

Cours Euronext Niveau 1 et carnet d'ordres

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Medexus Pharmaceuticals Inc (MDP) Actualités

Medexus Pharmaceuticals Inc (MDP)

Votre Hub pour des idées et discussions en direct en temps réel

MDP Actualités

Medexus to Participate in the 33rd Annual ROTH Conference on March 15-17, 2021

Medexus Achieves Record Revenue of $31.5 Million for the Third Quarter Fiscal 2021

Medexus Announces Expanded Availability of Gleolan® in Canada

Medexus Schedules Third Quarter Fiscal 2021 Conference Call

Medexus Announces Closing of $32.5 Million Public Offering, Including Exercise in Full of Over-Allotment Option

Medexus to Present at the Winter Wonderland Conference- Best Ideas from the Buy-Side

Medexus Announces Upsize to Previously Announced Bought Deal Public Offering

Medexus Announces $20 Million Bought Deal Public Offering of Units

Medexus Pharmaceuticals and medac GmbH enter into a License Agreement for First-in-Class Conditioning Agent for Hematopoietic...

Medexus Announces Renewal and Expansion of Canadian Distribution Agreement for NYDA®

Medexus Submits Application to List on the Nasdaq

Medexus Engages Independent Trading Group for Market Making Services

Medexus Announces Annual Equity Incentive Grants to Non-Executive Directors

Medexus Enters into Exclusive License to Register and Commercialize Triamcinolone Hexacetonide (TH) in the United States with...

Medexus to Present at The 13th Annual LD Micro Main Event Conference on December 15th

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

BLACK FRIDAY

Jusqu'à 65% de réduction sur Intégral

Cours Euronext Niveau 1 et carnet d'ordres